Autres langues Bright Minds Biosciences Inc.

Actions

DRUG

CA10919W4056

Temps Différé Canadian Securities Exchange Autres places de cotation 21:11:12 30/04/2024			Varia. 5j.	Varia. 1 janv.
1,29 ^CAD	-12,24%		-21,82%	-39,15%

12/02	Bright Minds Biosciences Inc. annonce ses résultats pour le premier trimestre clos le 31 décembre 2023	CI
2023	Bright Minds Biosciences Inc. annonce ses résultats pour l'exercice clos le 30 septembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Bright Minds Biosciences Inc. announced that it expects to receive $0.05416 million in funding	22/03
Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	12/02
Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	29/12
Bright Minds Biosciences : Announces Closing of Non-Brokered Private Placement Fully Subscribed by Management - Form 6-K	26/12
Bright Minds Biosciences Inc. announced that it has received $0.9 million in funding	22/12
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management	06/12
Bright Minds Biosciences Inc. announced that it expects to receive $0.9 million in funding	06/12
Bright Minds Biosciences : Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2023 and 2022 (Expressed in Canadian Dollars) - Form 6-K	15/08/23
Bright Minds Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	15/08/23
Top Midday Gainers	08/08/23
Bright Minds Biosciences on "Positive" qEEG Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101	08/08/23
Bright Minds Biosciences Brief: Announcing "Positive" qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101	08/08/23
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101	08/08/23
Bright Minds Biosciences Inc. Announces Positive qEEG (Quantitative Electroencephalogram) Data from Its First-In-Human Phase 1 Study of Lead Compound, Bmb-101	08/08/23
Bright Minds Biosciences : Announces Positive qEEG (Quantitative Electroencephalogram) Data fromits First-in-Human Phase 1 Study of Lead Compound, BMB-101	07/08/23
Bright Minds Biosciences Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101	20/07/23
Bright Minds Biosciences Inc. Announces Successful Completion of its Three-Part Phase 1 Study of BMB-101	20/07/23
Bright Minds Biosciences Brief: Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101	20/07/23
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101	20/07/23
CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)	12/07/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Bright Minds Biosciences Inc.

Actions

DRUG

CA10919W4056

Autres langues

Filtres